Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients With Comorbid Medical Illnesses
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Patients with severe mental illnesses have a higher risk of premature mortality than the general US population. Illnesses such as schizophrenia and bipolar disorder are frequently complicated by physical comorbidities such as diabetes and cardiovascular disease, including both coronary heart disease and cerebrovascular disease, which are associated with increased mortality and morbidity. Coronary heart disease is the leading cause of death among individuals with severe mental illnesses. Modifiable risk factors such as dyslipidemia, hyperglycemia, hypertension, smoking, and obesity are common in this population and contribute to risk for both diabetes and coronary heart disease. While many psychotropic medications used in the treatment of schizophrenia or bipolar disorder have similar efficacy, some medications are associated with more metabolic side effects than others, and clinicians should consider these risks when choosing among these medications. Patients with severe mental illnesses tend to have reduced access to health care and treatment for medical comorbidities compared with the general population. Therefore, clinicians involved in the care of this patient population should screen and monitor carefully for cardiometabolic side effects and risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 1×
“Adapted with permission from Allison et al.(19) 95% CI estimated from a randomized effects model.”
MethodScherk, H., Pajonk, F. G., & Leucht, S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.4.442 · Cited by 243
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
“Among the conventional AP, so-called low-potency agents, such as chlorpromazine and thioridazine, have a higher risk than high-potency drugs, such as haloperidol (110-112).”
BackgroundSelf-citationAlmost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“In general, it is concluded that AP add to the increased mortality risk of people with SMI either through direct cardio toxic effects or by impacting on weight gain [8,18].”
BackgroundCan bipolar disorder be viewed as a multi-system inflammatory disease?
Leboyer, M., Soreca, I., Scott, J., Frye, M., Henry, C., Tamouza, R., & Kupfer, D. J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.049 · Cited by 417
“…influence glucose metabolism, valproic acid is associated to weight gain and insulin resistance, second generation antipsychotics are associated to hyperlipidemia, increased risk with diabetes, and weight gain though the extent of weight gain depends on which antipsychotic is used (Newcomer, 2009).”
Background
Metadata
- Authors
- Newcomer, J. W.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-06
- Volume
- 70
- Issue
- suppl 3
- Pages
- 30-36
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2086560982
- Cited by
- 47
- References
- 2
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients With Comorbid Medical Illnesses. https://app.cochat.ai/papers/10.4088/jcp.7075su1c.05
- The paper
- Newcomer, J. W. (2009). Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients With Comorbid Medical Illnesses. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.7075su1c.05
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.